• 1
    Inada Y, Furukawa M, Sasaki H, et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 1995; 13: 8691.
  • 2
    Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992; 9: 249304.
  • 3
    Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol. 1995; 76: S228232.
  • 4
    Holle LM. Pegaspargase: an alternative? Ann Pharmacother. 1997; 31: 616624.
  • 5
    Chen SA, Sawchuk RJ, Brundage RC, et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther. 2000; 293: 248259.
  • 6
    Knüsli C, Delgado C, Malik F, et al. Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol. 1992; 82: 654663.
  • 7
    Tsunoda S, Ishikawa T, Yamamoto Y, et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent. J Pharmacol Exp Ther. 1999; 290: 368372.
  • 8
    Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem. 1996; 271: 2196921977.
  • 9
    Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000; 39: 1063410640.
  • 10
    Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000; 68: 556567.
  • 11
    Truitt GA, Tarby CM, Stem LL, Tamborini B, Bontempo JB, Nalin C. Pharmacodynamic and preliminary pharmacokinetic evaluation of pegylated derivatives of interferon-α-2a [abstract]. Proc Am Assoc Cancer Res. 1994; 35: 398 (Abstract 2370).
  • 12
    Jørgensen KE, Møller JV. Use of flexible polymers as probes of glomerular pore size. Am J Physiol. 1979; 236: F103111.
  • 13
    Bailon PS, Palleroni AV, inventors. Hoffman-La Roche AG, assignee. Interferon conjugates. European patent EP 0 809 996 A2. 1997.
  • 14
    Forti R, Schuffman S, Davies H, Mitchell W. Objective antiviral assay of the interferons by computer assisted data collection and analysis. Methods Enzymol. 1986; 119: 533540.
  • 15
    Meager A. Interferons alpha and beta. In: Cytokines. Englewood Cliffs, NJ: Prentice Hall, 1991: 180195.
  • 16
    Data on file. Investigator's Brochure: Information for the investigational product SCH 54031, PEG-Intron (peginterferon alfa-2b). Kenilworth, NJ: Schering-Plough, 1999.
  • 17
    Advances in the treatment of chronic hepatitis C: product monograph. Kenilworth, NJ: Schering-Plough Research Institute, 2000.
  • 18
    Multiple rising-dose safety and tolerance of PEG12000-Interferon alfa-2b (SCH 54031) administered subcutaneously in patients with chronic hepatitis C (data on file as I95-060-01). Kenilworth, NJ: Schering-Plough.
  • 19
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34: 395403.
  • 20
    Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996; 87: 30693081.
  • 21
    Talpaz M, O'Brien S, Rose E, et al. Phase I study of polythylene glycol formulation of interferon alpha-2B; (PEG Intron; Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001; 98: 17081713.
  • 22
    Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997; 337: 223229.
  • 23
    Kantarjian MH, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999; 17: 284292.
  • 24
    Talpaz M, Schiller G, Lipton J, et al. Phase I study of polyethylene glycol (PEG) interferon alpha-2b (PEG Intron) combined with cytosine arabinoside (Ara-C) in patients with CML [abstract]. Am Soc Clin Oncol. 2001; 20: 306a (Abstract 1221).
  • 25
    Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999; 94: 15171536.
  • 26
    Bukowski R, Ernstoff M, Gore M, et al. Phase I study of polyethylene glycol (PEG) interferon alpha-2B (PEG-INTRON) in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 1999; 446a. (Abstract 1719).